THE EFFECT OF HUMANIZED ANTIBODIES TO ANGPTL4 ON TRIGLYERIDES & VLDL-LEVELS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 高水平的甘油三酯和极低密度脂蛋白(也称为血脂异常)被广泛认为是冠心病和糖尿病发展的主要危险因素。这项研究测试了人源化ANGPTL4抗体通过激活脂蛋白脂酶来增加甘油三酯清除的能力。在这项原理验证研究中，我们确定了这些抗体是否能有效地降低肥胖的非人类灵长类动物的甘油三酯和极低密度脂蛋白，并改善血糖稳态。这些研究将在未来扩大，以调查长期治疗和对其他终点(即免疫功能的改善)的调查，这将导致一篇可发表的论文。这些研究使用了来自肥胖的NHP资源的动物。进展：这些研究已经完成。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. High levels of triglycerides and VLDL (also known as dyslipidemia) are widely accepted to be a major risk factor in the development of coronary heart disease and diabetes. This study tested the ability humanized ANGPTL4 antibodies to increase triglyceride clearance through activation of the lipoprotein lipase enzyme. In this proof of principle study we determined whether these antibodies can effectively reduce triglycerides and VLDL and improve glucose homeostasis in obese nonhuman primates. These studies will be expanded in the future to investigate prolonged treatment and investigation of other endpoints (i.e., improvement in immune function) that will lead to a publishable paper. These studies used animals from the Obese NHP Resource. Progress: These studies have been completed.